Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-04-11 00:00:00 ET · period of report 2024-04-10 · accession 0001787306-24-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-11 | 2024-04-10 | ARQT | Topper David Joseph | CFO | A - Grant | $0.00 | +110.0K | 110.0K | New | $0 |
| D | 2024-04-11 | 2024-04-10 | ARQT | Topper David Joseph | CFO | A - Grant | $0.00 | +310.0K | 310.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-10 | A | A | 110,000 | $0.00 | 110,000 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest as to 25% of the RSUs on each annual anniversary of April 10, 2024, subject to the Reporting Person's continued service through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2024-04-10 | A | A | 310,000 | $0.00 | 310,000 | D | $12.34 · — to 2034-04-10 | 310,000 Common Stock | (F2) The option will vest and become exercisable as to 25% of the shares on the first annual anniversary of the grant date of April 10, 2024, and the remaining options will vest at 2.0833%, on each monthly anniversary thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |